&nbsp;

GoalsOfCarePoster-FR.pdf

Oct 2021

Document

GOC-DocumentationTemplate-FR.pdf

Oct 2021

Document

GOC-DocumentationTemplate.pdf

Oct 2021

Regimen

ENFO

Cancer Type:

Genitourinary,

Bladder / Urothelial

Intent: Palliative

Funding:

New Drug Funding Program

Enfortumab Vedotin - Previously Treated Advanced or Metastatic Urothelial Cancer

Drugs Used:

enfortumab vedotin

Quick Link(s):

Regimen Monograph

Jan 2025

Regimen

ERDA

Cancer Type:

Genitourinary,

Bladder / Urothelial

Intent: Palliative

Drugs Used:

erdafitinib (Unfunded)

Quick Link(s):

Regimen Monograph

Nov 2021

Regimen

ENHE

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Trastuzumab Deruxtecan - Unresectable Locally Advanced or Metastatic Breast Cancer

New Drug Funding Program

Trastuzumab Deruxtecan - HER2-low Unresectable Locally Advanced or Metastatic Breast Cancer

Enhertu trastuzumab deruxtecan

Drugs Used:

Quick Link(s):

Regimen Monograph

Drug

gemtuzumab ozogamicin

Other Name(s): Mylotarg®

Quick Link(s):

Drug Monograph, Patient Info Sheet

Dec 1969

Regimen

GILT

Cancer Type:

Hematologic,

Leukemia - Acute Myeloid (AML)

Intent: Palliative

Funding:

Exceptional Access Program

gilteritinib - Relapsed or Refractory FLT3-mutated acute myeloid leukemia

Drugs Used:

gilteritinib

Quick Link(s):

Regimen Monograph

Mar 2022

Document

EndometrialCancerDiagnosisPathwayMap.pdf

Dec 1969

Document

EndometrialCancerTreatmentPathwayMap.pdf

Dec 1969

Regimen

ENTR

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

Exceptional Access Program

entrectinib - For the treatment of locally advanced (not amenable to curative therapy) or metastatic NSCLC, according to clinical criteria

Drugs Used:

entrectinib